healthneutral
Diabetes Drug's Impact on Kidney Health
Monday, December 30, 2024
But here's where things get interesting. Empagliflozin isn't cheap. So, researchers wanted to know if it's worth the cost. They did something called a cost-effectiveness analysis. This involves looking at the health benefits of a treatment and comparing them to the costs. And guess what? Empagliflozin passed the test.
Some say it's like buying insurance for your kidneys. But is it really that simple? While the drug looks good on paper, there are still questions about its long-term effects and how it works in real-world settings. Plus, not everyone with CKD needs it. It's all about weighing the pros and cons.
So, the next time you hear about Empagliflozin, remember it's not just about blood sugar. It's about giving the kidneys a fighting chance too.
Actions
flag content